zealand pharma glucagon

Zealand Pharma Glucagon: Key Product Attributes & Composition Guide

Published: July 18, 2026 14:40 Author: Soo-Jin Torres

Abstract: Zealand Pharma’s glucagon portfolio, including dasiglucagon, leverages advanced peptide synthesis for rapid hypoglycemia reversal. Compared to legacy brands (e.g., Eli Lilly’s Glucagon), it offers superior thermostability and a ready-to-use pen format, eliminating reconstitution errors. Market trends show a 12.4% CAGR (2024-2030) for peptide-based rescue therapies, driven by diabetes prevalence. Zealand holds FDA/EMA approvals with cGMP-certified facilities. Key parameters: 0.6 mg dose, 10-minute onset, 24-hour stability at 30°C. Advantages include reduced injection pain; limitations involve higher cost. Selection criteria prioritize storage logistics (2-8°C cold chain) and regulatory compliance. Industry outlook favors non-injectable peptide delivery systems.

Purchasing Tips: Key Facts About Zealand Pharma Glucagon

Published: July 15, 2026 17:23 Author: Mark Lemoine

Abstract: Zealand Pharma’s glucagon analog (dasiglucagon) leverages a proprietary peptide backbone for enhanced stability, addressing hypoglycemia with a 10-minute onset vs. 2-3 hours for traditional glucagon. Market trends show a 12.5% CAGR (2024-2030) in peptide therapeutics, with Zealand competing against Eli Lilly’s Baqsimi (nasal) and Xeris’s Gvoke (liquid-stable). Dasiglucagon’s key advantage is room-temperature stability (no reconstitution), while its disadvantage is higher cost ( $300/dose). Product parameters: 0.6 mg subcutaneous injection, pH 7.4 buffer. Applications extend to congenital hyperinsulinism. Zealand holds FDA/EMA approvals (2021, 2023) and ISO 13485 certification. Selection tips prioritize stability, onset speed, and cold-chain logistics (2-8°C for competitors). Industry data indicates 45% of patients prefer prefilled auto-injectors.